HOME >> MEDICINE >> NEWS
Hopkins Researchers Develop New Therapy For Autoimmune Disorders Such As Rheumatoid Arthritis And Lupus

Researchers at the Johns Hopkins Oncology Center used high doses of the chemotherapy drug cyclophosphamide alone to control previously untreatable forms of autoimmune disorders such as rheumatoid arthritis, lupus and hemolytic anemia.

Their findings are reported in the December 15, 1998 issue of Annals of Internal Medicine.

Of eight patients treated in the study with stand-alone high dose cyclophosphamide, five reported complete remissions and two achieved and maintained partial remissions. Four patients treated from six months to more than a year ago remain disease free, and two patients, in partial remission, continue to improve after more than a year. In addition, all patients were able to decrease their doses of medication, and three patients have completely discontinued medications for their disease. These patients had not responded to disease therapies and suffered from recurrent infections, persistent pain and kidney problems.

Treatment for severe autoimmune diseases using high-dose cyclophosphamide followed by bone marrow or stem cell transplantation to repopulate the immune system destroyed by the drug treatment is being studied elsewhere. The new Hopkins research, funded by the National Institutes of Health, suggests that transplants are unnecessary. "Stem cells, the marrow cells that reconstitute the immune system, are resistant to the drug and will repopulate in the marrow, without the need for transplantation," says Robert Brodsky, M.D., assistant professor of oncology and medicine and lead author of the study. "High-dose cyclophosphamide, without stem cell or bone marrow reinfusion, appears to be safer for the patient and avoids reinfusion of diseased immune cells," adds Brodsky, an American Society of Hematology Junior Faculty Scholar.

Hopkins scientists believe the cyclophosphamide works by reprogramming the immune system. "Immunity is learned' not inherited," explains Richard Jones, M.D., associat
'"/>

Contact: Vanessa Gatto
gattova@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
15-Dec-1998


Page: 1 2

Related medicine news :

1. Hopkins begins human trials with donor adult stem cells to repair muscle damaged from heart attack
2. Earlier use of prostate cancer vaccines urged by Hopkins scientists
3. Hopkins convenes consensus conference to develop blueprint for nationwide matching program
4. Johns Hopkins scientists receive presidential medals
5. Hopkins Institute for Global Tobacco Control receives elite recognition from PAHO/WHO
6. Hunt for autism genes to be led by Hopkins researchers
7. Most household cleaners remove peanut allergens, Hopkins study shows
8. Exercise Hypertension occurs when cells cant relax, Hopkins researchers find
9. Hopkins young researchers honored for their contributions
10. Hopkins researchers find MRI useful tool in diagnosing inflammatory bowel diseases in children
11. Hopkins Peter Agre receives 2003 Nobel Prize in chemistry

Post Your Comments:
(Date:11/27/2014)... 2014 Blood-borne pathogens raise the risk ... and procedures in place to counter this. However, it ... things tainted with menstrual blood are taken as seriously. ... more sanitary way to handle tampons and menstrual pads ... Sonora, Calif. , He then created a prototype of ...
(Date:11/27/2014)... (HealthDay News) -- Most babies and young children don,t ... Food and Drug Administration says. Over-the-counter (OTC) cold ... younger than 2 because they could cause serious and ... adults average about three colds a year, but children ... parents might want to give them pain relievers, decongestants ...
(Date:11/27/2014)... NC (PRWEB) November 27, 2014 ... 12 years in the Charlotte area providing audits, ... examination services to businesses of varying size across ... business owners to meet all of their accounting ... certification through the QuickBooks ProAdvisor Program. When asking ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “Wekho” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review ... follow locations instead of people. , An interesting new way ... for iOS and Android devices. It’s called Wekho and ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
(Date:11/26/2014)...  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... On Tuesday, December 2, the company will participate ... Conference.  D. Keith Grossman , President and Chief ... beginning at 11:30 a.m., Eastern Standard Time (8:30 a.m., ...
(Date:11/26/2014)...  Cohen, Placitella & Roth, PC is investigating ... Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 31, 2011 through November 2, 2014 ("Class Period").  ... its officers and directors publically disseminated materially false ... and 20(a) of the Securities Exchange Act of ...
(Date:11/26/2014)... 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... Drug Administration (FDA) has issued a Complete Response ... AVP-825. AVP-825 is an investigational drug-device combination product ... a novel Breath Powered delivery technology. ... with the preliminary feedback announced on November 7, ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
Cached News: